conflict of interest

Krimsky warned strenuously about the corrupting power of money in science.

Authors of papers published in JAMA and NEJM received millions in undisclosed payments in 2017, an analysis finds.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

The nonprofit newsroom has collected more than 29,000 disclosures of faculty members’ outside income, but they represent just the tip of the iceberg.

A drive for revenue is damaging basic science.

Information made public by US Senator Chuck Grassley reveals that a handful of allegations have recently been referred to federal investigators.

A new study suggests that sponsors downplay their influence when reporting trials carried out in collaboration with academic researchers.

José Baselga of Memorial Sloan Kettering took millions of dollars from drug and health care companies but did not report the payments in his research articles.

The company’s announcement comes weeks after enrollment was suspended.

The EPA administrator had a sweet rental deal from a DC lobbyist, took pricey flights, and engineered whopping pay raises for aides.

An email exchange and an unusual meeting suggest a connection between an institute’s pursuit of industry support and the rejection of a grant application.

The editorial board at the International Journal of Occupational and Environmental Health accuses its publisher of promoting corporate interests.

The authors of two new studies on the payments suggest stricter guidelines are needed.

The proposed changes follow revelations in recent years that committee members preparing reports for the Academies did not disclose industry relationships. 

Expressions of concern will also be linked in study summaries. 

Three investigations reveal the influence of industry money in patient advocacy groups, treatment guidelines, and Twitter feeds. 

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

Few authors make their full data available and most published papers do not clearly state funding sources and conflicts of interest.

Journalists and activists use the Freedom of Information Act to expose academics’ relationships with industry.